Four novel RUNX2 mutations including a splice donor site result in the cleidocranial dysplasia phenotype
- 3 November 2005
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 207 (1), 114-122
- https://doi.org/10.1002/jcp.20552
Abstract
Cleidocranial dysplasia (CCD) is an autosomal dominant disorder caused by haploinsufficiency of the RUNX2 gene. In this study, we analyzed by direct sequencing RUNX2 mutations from eleven CCD patients. Four of seven mutations were novel: two nonsense mutations resulted in a translational stop at codon 50 (Q50X) and 112 (E112X); a missense mutation converted arginine to glycine at codon 131 (R131G); and an exon 1 splice donor site mutation (donor splice site GT/AT, IVS1 + 1G > A) at exon 1–intron junction resulted in the deletion of QA stretch contained in exon 1 of RUNX2. We focused on the functional analysis of the IVS1 + 1G > A mutation. A full‐length cDNA of this mutation was cloned (RUNX2Δe1) and expressed in Chinese hamster ovary (CHO) and HeLa cells. Functional analysis of RUNX2Δe1 was performed with respect to protein stability, nuclear localization, DNA binding, and transactivation activity of a downstream RUNX2 target gene. Protein stability of RUNX2Δe1 is similar to wild‐type RUNX2 as determined by Western blot analysis. Subcellular localization of RUNX2Δe1, assessed by in situ immunofluorescent staining, was observed with partial retention in both the nucleus and cytoplasm. This finding is in contrast to RUNX2 wild‐type, which is detected exclusively in the nucleus. DNA binding activity was also compromised by the RUNX2Δe1 in gel shift assay. Finally, RUNX2Δe1 blocked transactivation of the osteocalcin gene determined by transient transfection assay. Our findings demonstrate for the first time that the CCD phenotype can be caused by a splice site mutation, which results in the deletion of N‐terminus amino acids containing the QA stretch in RUNX2 that contains a previously unidentified second nuclear localization signal (NLS). We postulate that the QA sequence unique to RUNX2 contributes to a competent structure of RUNX2 that is required for nuclear localization, DNA binding, and transactivation function. J. Cell. Physiol. 207: 114–122, 2006.Keywords
This publication has 37 references indexed in Scilit:
- Transcriptional regulation of chondrocyte maturation: Potential involvement of transcription factors in OA pathogenesisMolecular Aspects of Medicine, 2005
- Regulatory Controls for Osteoblast Growth and Differentiation: Role of Runx/Cbfa/AML FactorsCritical Reviews™ in Eukaryotic Gene Expression, 2004
- Six novel mutations of theRUNX2 gene in Italian patients with cleidocranial dysplasiaHuman Mutation, 2003
- The Protein Kinase C Pathway Plays a Central Role in the Fibroblast Growth Factor-stimulated Expression and Transactivation Activity of Runx2Journal of Biological Chemistry, 2003
- Cbfβ interacts with Runx2 and has a critical role in bone developmentNature Genetics, 2002
- The core-binding factor β subunit is required for bone formation and hematopoietic maturationNature Genetics, 2002
- Core-binding factor β interacts with Runx2 and is required for skeletal developmentNature Genetics, 2002
- Okadaic acid stimulates osteopontin expression through de novo induction of AP‐1Journal of Cellular Biochemistry, 2002
- Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasiaNature Genetics, 1997
- Activity of the rat osteocalcin basal promoter in osteoblastic cells is dependent upon homeodomain and CP1 binding motifsMolecular Endocrinology, 1994